

**Sinclair Pharma plc (“Sinclair” or the “Company”)  
Grant of share awards**

Sinclair Pharma plc ("Sinclair" or "the Company": SPH:L), the international specialty pharma company, announces that on 4 October 2010 shares were issued in relation to performance share awards that vested under the 2003 Executive Share Incentive Plan to Alan Olby, CFO, and Stephen Redman, Legal Director and Company Secretary. The details of the awards are set out below:

<b>Name</b>	<b>Exercise Price</b>	<b>Shares allotted</b>	<b>Total options and share awards held</b>
Alan Olby	1p	52,127	171,748
Stephen Redman	1p	40,017	190,000

**For further information please contact:**

**Sinclair Pharma plc** Tel: +44 (0)1483 410 600  
Chris Spooner, CEO  
Alan Olby, CFO

**Singer Capital Markets Ltd** Tel: +44 (0)20 3205 7500  
Shaun Dobson  
Claes Spång

**Biddicks, Financial Public Relations** Tel: +44 (0)20 7448 1000  
Shane Dolan

**Notes to Editors:**

**About Sinclair Pharma Plc** [www.sinclairpharma.com](http://www.sinclairpharma.com)

Sinclair Pharma plc is an international specialty pharmaceutical company providing solutions to treat wounds, dermatological and oral diseases through advanced surface technology and innovative delivery systems. It has a growing sales and marketing operation that is present in France, Italy, Germany and Spain, and an extensive marketing partner network across selected developed and emerging markets.

*"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.*